Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1014 studies found for:    BCR
Show Display Options
Rank Status Study
1 Not yet recruiting Phase II Front-line Treatment of Adult Affected of Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia (ALL) With Ponatinib.
Conditions: Philadelphia Positive;   BCR-ABL Positive;   Acute Lymphoblastic Leukemia
Intervention: Drug: Ponatinib
2 Recruiting Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Conditions: Chronic Phase Philadelphia Positive;   BCR-ABL Positive;   Chronic Myeloid Leukaemia
Intervention:
3 Completed Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
Condition: Leukemia, Myeloid
Intervention: Drug: Nilotinib
4 Terminated Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL
Condition: Acute Lymphoblastic Leukemia
Intervention:
5 Active, not recruiting Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
Conditions: Leukemia;   Leukemia, Myeloid;   Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Philadelphia Chromosome;   Hematologic Diseases
Intervention: Drug: Radotinib
6 Completed
Has Results
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Omacetaxine mepesuccinate
7 Active, not recruiting Nilotinib in PH+, BCR-, ABL+ CML Patients
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
8 Completed Safety Assessment of a Multipeptide-gene Vaccine in CML
Condition: Leukemia, Myeloid, Chronic
Interventions: Biological: Bcr-abl multipeptide vaccine;   Genetic: Cytokine gene adjuvant
9 Recruiting Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML
Conditions: Chronic Myeloid Leukemia in Myeloid Blast Crisis;   Untreated Adult Acute Myeloid Leukemia
Intervention: Drug: Nilotinib+AD induction
10 Completed Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: imatinib;   Drug: cyclophosphamide;   Drug: daunorubicin;   Drug: vincristine;   Drug: prednisolone;   Drug: methotrexate;   Drug: cytarabine;   Drug: dexamethasone
11 Terminated
Has Results
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Condition: Leukemia
Interventions: Biological: bcr-abl peptide vaccine;   Genetic: reverse transcriptase-polymerase chain reaction
12 Active, not recruiting Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL
Conditions: Acute Lymphoblastic Leukemia;   Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Dasatinib;   Drug: Methotrexate;   Drug: Ara-C
13 Recruiting Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Condition: Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF  (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
14 Completed A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
Conditions: Myelofibrosis;   Myeloid Metaplasia;   Agnogenic Myeloid Metaplasia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: Imatinib mesylate
15 Recruiting Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
Condition: Chronic Myeloid Leukemia
Intervention: Behavioral: Dasatinib discontinuation
16 Recruiting Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Condition: Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia
Intervention: Drug: Nilotinib
17 Recruiting Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Conditions: Leukemia;   Leukemia,Pediatric;   Leukemia, Myleiod;   Leukemia, Mylegenous, Chronic;   Leukemia, Mylegenous, Accelerated;   BCR-ABL Positive;   Myeloproliferative Disorder;   Bone Marrow Disease;   Hematologic Diseases;   Neoplastic Processes;   Imatinib;   Dasatinib;   Enzyme Inhibitor;   Protein Kinase Inhibitor
Intervention: Drug: nilotinib
18 Active, not recruiting Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: nilotinib;   Drug: imatinib mesylate;   Other: pharmacological study
19 Active, not recruiting Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study
Conditions: Treatment;   Stem Cell Transplantation
Interventions: Drug: Nilotinib;   Drug: Imatinib
20 Recruiting Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years
Condition: Acute Lymphoblastic Leukemia Ph Positive
Interventions: Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Vincristine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years